Roche Halts Development of Obesity Drug Candidate
Roche has halted the development of emugrobart, a muscle-preserving obesity drug candidate, following a failed interim analysis.
11 trends tracked about this subject — the full history, oldest to newest below.
Roche has halted the development of emugrobart, a muscle-preserving obesity drug candidate, following a failed interim analysis.
Roche's experimental drug sefaxersen meets its primary endpoint in a late-stage study for the autoimmune disease IgAN.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Roche has secured a global licensing pact with Simcere Zaiming for an experimental B-cell-targeting antibody.
BioNTech and Genentech have terminated a phase 2 mRNA colorectal cancer vaccine trial after safety reviews revealed more deaths than in the control group.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
The FDA has granted clearance to a first-of-its-kind blood test for Alzheimer's biomarkers developed through a partnership between Roche and Eli Lilly.
Advances in Alzheimer's blood tests are promising earlier diagnosis but triggering significant emotional distress and confusion for patients.
A new generation of Alzheimer's treatments, including Roche's brainshuttle therapy, may stop the disease before symptoms even appear.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.